Ava’s wearable helps women determine their fertile window
Ava, a Swiss medical technology company focused on innovations in women’s health, has raised $9.7 million in a strategic Series A round led by European VC firm Polytech Ecosystem Ventures. The funds will fuel further product development and clinical research, scale production and support expansion into Europe and other new markets.
The Ava bracelet uses a patented big data approach to precisely detect a woman’s entire fertile window in real time. The company is working on clinical studies to expand its algorithms for use in both pregnancy recognition, pregnancy monitoring, and possible use as a non-hormonal contraceptive device. With research and product development based in Zurich, Ava’s US headquarters are in San Francisco.
Read more: Startupticker.ch
This post was originally published on Tech.eu.